Skip to main content
. 2023 Jan 16;13(1):182. doi: 10.3390/biom13010182

Table 2.

Descriptive statistics of the patients’ dataset, with statistical comparison between Amb a 11-positive and -negative subsets.

Parameters Patients Group
(n = 150)
Amb a 11 Positive (n = 103) Amb a 11 Negative
(n = 47)
p Value
Age (years) 35.91 ± 8.75 (18–61, 35) 36.04 ± 8.93 (18–61, 35) 35.62 ± 8.43 (20–61, 34) >0.05 NS
Age groups 18–39 years: 106 (70.67%)
40–54 years: 39 (26%)
≥55 years: 5 (3.33%)
18–39 years: 73 (70.88%)
40–54 years: 27 (26.21%)
≥55 years: 3 (2.91%)
18–39 years: 33 (70.21%)
40–54 years: 12 (25.53%)
≥55 years: 2 (4.26%)
>0.05 NS
Sex Women: 50 (33.33%)
Men: 100 (66.67%)
Women: 38 (36.89%)
Men: 65 (63.11%)
Women: 12 (25.53%)
Men: 35 (74.47%)
<0.05 S
Allergy history (years) 5.06 ± 4.96 (1–32, 3) 5.28 ± 4.84 (1–24, 3) 4.56 ± 5.23 (1–32, 3) >0.05 NS
Family history of allergic disease Negative: 107 (71.33%)
Positive: 43 (28.67%)
Negative: 72 (69.9%)
Positive: 31 (30.1%)
Negative: 35 (74.47%)
Positive: 12 (25.53%)
>0.05 NS
Exposure factors
Smoking Non-smokers: 89 (59.33%)
Smokers: 61 (40.67%)
Non-smokers: 61 (59.22%)
Smokers: 42 (40.78%)
Non-smokers: 28 (59.57%)
Smokers:19 (40.43%)
>0.05 NS
Professional (organic solvents, dust, etc.) Negative: 122 (81.33%)
Positive: 28 (18.67%)
Negative: 84 (81.55%)
Positive: 19 (18.45%)
Negative: 38 (80.85%)
Positive: 9 (19.15%)
>0.05 NS
Pets Negative: 96 (64%)
Positive: 54 (36%)
Negative: 71 (68.93%)
Positive: 32 (31.07%)
Negative: 25 (53.19%)
Positive: 22 (46.81%)
<0.05 S
Clinical data
Allergy pattern Monosensitized: 45 (30%)
Polysensitized: 105 (70%)
Monosensitized: 38 (36.89%)
Polysensitized: 65 (63.11%)
Monosensitized: 7 (14.89%)
Polysensitized: 40 (85.11%)
<0.05 S
Additional positive skin prick test results House dust mite: 54 (36%)
Cereal/grass pollen: 48 (32%)
Artemisia: 42 (28%)
Fungi: 27 (18%)
Tree pollen: 25 (16.67%)
House dust mite: 35 (33.98%)
Cereal/grass pollen: 26 (25.24%)
Artemisia: 24 (23.3%)
Fungi: 15 (14.56%)
Tree pollen: 13 (12.62%)
House dust mite: 19 (40.43%)
Cereal/grass pollen: 22 (46.81%)
Artemisia: 18 (38.30%)
Fungi: 12 (25.53%)
Tree pollen: 12 (25.53%)
>0.05 NS
<0.05 S
<0.05 S
<0.05 S
<0.05 S
Allergy season (months) 3.24 ± 1.86 (1–12, 3) 3.06 ± 1.74 (1–12, 2) 3.66 ± 2.06 (1–12, 3) >0.05 NS
Symptoms score
(on a 1–12 scale for rhinitis/asthma,
1–9 scale for conjunctivitis/urticaria)
and frequency of disease
Rhinitis: 7.27 ± 2.80 (1–12, 8)
149 patients (99.33%)
Conjunctivitis: 4.58 ± 2.3 (1–9, 4)
136 patients (90.67%)
Asthma: 3.47 ± 2.38 (1–11, 3)
90 patients (60%)
Urticaria: 3.11 ± 1.87 (1–9, 3)
37 patients (24.67%)
Edema: 13 patients (8.67%)
Rhinitis: 7.30 ± 2.88 (1–12, 8)
103 patients (100%)
Conjunctivitis: 4.6 ± 2.43 (1–9, 4)
95 patients (92.23%)
Asthma: 3.84 ± 2.54 (1–11, 3)
63 patients (61.17%)
Urticaria: 3.17 ± 2.04 (1–9, 3)
24 patients (23.3%)
Edema: 8 patients (7.77%)
Rhinitis: 7.20 ± 2.66 (1–12, 8)
46 patients (97.87%)
Conjunctivitis: 4.54 ± 2.01 (1–9, 5)
41 patients (87.23%)
Asthma: 2.59 ± 1.69 (1–6, 2)
27 patients (57.45%)
Urticaria: 3 ± 1.58 (1–6, 3)
13 patients (27.66%)
Edema: 5 patients (10.64%)
>0.05 NS
>0.05 NS
>0.05 NS
>0.05 NS
<0.05 S
>0.05 NS
>0.05 NS
>0.05 NS
>0.05 NS
Quality of Life indicators
Sleep disturbance Absent: 48 (32%)
Present: 102 (68%)
Absent: 31 (30.1%)
Present: 72 (69.9%)
Absent: 17 (36.17%)
Present: 30 (63.83%)
>0.05 NS
Allergy-related hospitalization Absent: 133 (88.67%)
Present: 17 (21.33%)
Absent: 88 (85.44%)
Present: 15 (14.56%)
Absent: 45 (95.74%)
Present: 2 (4.26%)
>0.05 NS
Activity impairment score (1–10 scale) 6.88 ± 2.62 (1–10, 7.5) 7.09 ± 2.60 (1–10, 8) 6.43 ± 2.64 (1–10, 7) >0.05 NS

Numerical variables presented as: mean ± standard deviation (minimum–maximum and median). Categorical variables presented as: frequency (cases) and percentage.